| These highlights do not include all the information needed to use EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, EMTRICITABINE and TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006 | Bryant Ranch Prepack | 20251104 | 100 |
| These highlights do not include all the information needed to use EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006 | Laurus Labs Limited | Laurus Labs Limited (VSP2) | 20250728 | 3 |
| These highlights do not include all the information needed to use EFAVIRENZ safely and effectively. See full prescribing information for EFAVIRENZ TABLETS EFAVIRENZ tablets, for oral use Initial U.S. Approval: 1998 | Macleods Pharmaceuticals Limited | 20240628 | 2 |
| These highlights do not include all the information needed to use EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, EMTRICITABINE and TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006 | Teva Pharmaceuticals USA, Inc. | 20240528 | 7 |
| These highlights do not include all the information needed to use EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2018 | Laurus Labs Limited | Laurus Labs Limited (VSP2) | 20240507 | 2 |
| These highlights do not include all the information needed to use EFAVIRENZ TABLETS safely and effectively. See full prescribing information for EFAVIRENZ TABLETS. EFAVIRENZ tablets, for oral use Initial U.S. Approval: 1998 | Cipla USA Inc. | CIPLA LIMITED GOA | 20240331 | 7 |
| These highlights do not include all the information needed to use EFAVIRENZ CAPSULES safely and effectively. See full prescribing information for EFAVIRENZ CAPSULES. EFAVIRENZ capsules for oral use Initial U.S. Approval: 1998 | Aurobindo Pharma Limited | 20231229 | 7 |
| These highlights do not include all the information needed to use EFAVIRENZ TABLETS safely and effectively. See full prescribing information for EFAVIRENZ TABLETS. EFAVIRENZ tablets, for oral use Initial U.S. Approval: 1998 | Aurobindo Pharma Limited | 20231229 | 10 |
| These highlights do not include all the information needed to use EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, EMTRICITABINE and TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006 | Aurobindo Pharma Limited | 20231228 | 5 |
| These highlights do not include all the information needed to use EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2018 | Laurus Labs Limited | Laurus Labs Limited (VSP2) | 20231115 | 2 |
| These highlights do not include all the information needed to use EFAVIRENZ TABLETS safely and effectively. See full prescribing information for EFAVIRENZ TABLETS. EFAVIRENZ tablets for oral use Initial U.S. Approval: 1998 | Camber Pharmaceuticals, Inc. | Hetero Labs Limited Unit III | 20230515 | 3 |
| These highlights do not include all the information needed to use EFAVIRENZ TABLETS safely and effectively. See full prescribing information for EFAVIRENZ TABLETS. EFAVIRENZ tablets for oral use Initial U.S. Approval: 1998 | XLCare Pharmaceuticals Inc. | Evaric Pharmaceuticals Inc | 20230112 | 2 |
| These highlights do not include all the information needed to use EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, EMTRICITABINE and TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006 | Camber Pharmaceuticals, Inc. | Annora Pharma Private Limited | 20220728 | 1 |
| These highlights do not include all the information needed to use EFAVIRENZ, EMTRICITABINE and TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, EMTRICITABINE and TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006 | Macleods Pharmaceuticals Limited | 20210918 | 1 |
| These highlights do not include all the information needed to use EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE TABLET safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE TABLET. EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006 | Exelan Pharmaceuticals, Inc. | Genvion Corporation 500 Camiel Sys Street, Winnipeg, Manitoba R2J 4K2, Canada | 20210312 | 1 |
| These highlights do not include all the information needed to use EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE TABLET safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE TABLET. EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006 | Cipla USA Inc. | Cipla Patalganga | Genvion Corporation 500 Camiel Sys Street, Winnipeg, Manitoba R2J 4K2, Canada | 20210311 | 3 |
| These highlights do not include all the information needed to use SYMFI safely and effectively. See full prescribing information for SYMFI . SYMFI ® (efavirenz, lamivudine and tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2018 | Viatris Specialty LLC | 20191015 | 6 |
| These highlights do not include all the information needed to use ATRIPLA safely and effectively. See full prescribing information for ATRIPLA. ATRIPLA ® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets Initial U.S. Approval: 2006 | DOH CENTRAL PHARMACY | 20170123 | 3 |
| These highlights do not include all the information needed to use ATRIPLA safely and effectively. See full prescribing information for ATRIPLA. ATRIPLA ® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2006 | Physicians Total Care, Inc. | 20130503 | 3 |
| These highlights do not include all the information needed to use SUSTIVA safely and effectively. See full prescribing information for SUSTIVA. SUSTIVA ® (efavirenz) capsules for oral use SUSTIVA ® (efavirenz) tablets for oral use Initial U.S. Approval: 1998 | Physicians Total Care, Inc. | 20130102 | 2 |